Table 2 Characteristics of treatment modalities in patients with LA-HNSCC
Treatment | Number (%) | |
|---|---|---|
Induction chemotherapy | n = 158 | |
Regimen | Docetaxel + Cisplatin | 77 (48.7%) |
Docetaxel + Cisplatin + Fluorouracil | 42 (26.6%) | |
Fluorouracil + Cisplatin | 28 (17.7%) | |
Others | 11 (7.0%) | |
Number of cycles | Median: 3 cycles | Range 1–5 |
Best overall response | Complete response | 25 (15.8%) |
Partial response | 87 (55.1%) | |
Stable disease | 31 (19.6%) | |
Progressive disease | 15 (9.5%) | |
Definitive Concurrent chemoradiotherapy (CCRT) | n = 229 | |
CCRT regimen | Weekly cisplatin | 133 (58.1%) |
3-weekly cisplatin | 63 (27.5%) | |
Fluorouracil + Cisplatin | 22 (9.6%) | |
Others | 11 (4.8%) | |
Total radiation dose (Gy) | Mean: 62.5 / Median: 67.5 Gy | Range 32–72 |
Best overall response | Complete response | 148 (65.2%) |
Partial response | 42 (18.5%) | |
Stable disease | 21 (9.3%) | |
Progressive disease | 16 (7.1%) | |